skip to main content

News Archive

Date: 03/14/2022
A new clinical trial from a team at the University of Michigan Rogel Cancer Center uses innovative basic science research methods to offer hope and a new treatment to glioblastoma patients. A collaborative team of Rogel physicians, led by Daniel Wahl, M.D., Ph.D., hopes that grounding their trial in rigorous and innovative biology from the very beginning will help this approach succeed where so many other potential glioblastoma treatments have failed.
Date: 03/14/2022
Meet Madison McTevia, M.A., C.C.L.S., clinical specialist and program coordinator for the Families Facing Cancer program at the Rogel Cancer Center. And, meet Kevin (or "Kev" as he affectionally known) her 210-pound potbelly pig.
Date: 03/11/2022
Paul Swiecicki, M.D., has been named medical director for the Clinical Research Specimen Processing (CRSP) laboratory at the U-M Rogel Cancer Center. Swiecicki, along with lab manager Keri Innes, will oversee the lab's expansion into an additional space on the Rogel building's 7th floor to accommodate an increasing workload. The laboratory is responsible for managing bio-specimens for all clinical oncology trials in progress at Rogel Cancer Center.
Date: 03/07/2022
Crowdfunding has become a means for people with cancer to get help managing the financial impact of their disease. But while there’s relief in paying bills, a new study finds that it comes at a cost: a sense of shame and stigma from asking for help and revealing personal health details.
Date: 03/03/2022
Researchers at the University of Michigan Rogel Cancer Center found that a cytokine, a category of protein that acts as messengers in the body, and a fatty acid can work together to trigger a type of cell death previously defined by studies with synthetic molecules.
Date: 03/03/2022
The surgeons at 21 melanoma referral centers collaborated to see whether these revelations had created changes in treatment plans for high-risk melanoma. It can often take significant time — as long as a decade — for providers to adopt or deescalate cancer treatments, even if the available evidence supports a shift in the landscape.
Date: 02/24/2022
A new phase II trial finds that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control.
Date: 02/16/2022
In 2005, Arul Chinnaiyan, M.D., Ph.D., and his lab found when a gene regulated by androgens called TMPRSS2 fuses with a transcription factor called ERG, it triggers the development of prostate cancer. This gene fusion was the first ever identified in solid tumors. In the nearly two decades since, the Chinnaiyan lab has refined its discovery, understanding how the hormone androgen regulates this gene fusion and developing a urine-based screening test to better detect prostate cancer.
Date: 02/13/2022
Arul M. Chinnaiyan, M.D., Ph.D., was awarded the 2022 Sjöberg Prize by the Royal Swedish Academy of Sciences, which also awards Nobel Prizes. Chinnaiyan is being honored for the discovery of recurrent gene fusions in prostate cancer, a groundbreaking finding initially published in 2005 that has led to a better understanding of how prostate cancer develops and improved methods to detect the disease.
Date: 02/10/2022
Evan Keller, D.V.M., Ph.D., associate director of shared resources at the Rogel Cancer Center, has been appointed to a new directorship in the University of Michigan’s Office of the Vice President for Research, according to Vice President for Research Rebecca Cunningham, M.D.